Advances in Pharmacological Treatment
Monday 25th April 2022, 2 PM (Central European Summer Time)
Duration 90 minutes
Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. While some individuals with schizophrenia experience treatment refractoriness from the outset, others develop refractoriness during the course of illness after having initially responded to treatment. About 15% of the patients diagnosed with schizophrenia have a single episode, ca. 85% has variable course and unfortunately one third – or depending on the defiition 40-60% - of them do not respond to antipsychotic treatment as expected, or at all. The most frequently used defiition of treatment resistant schizophrenia (TRS) is - less than 20% improvement after two adequate trials with two different antipsychotic drugs.Accumulating evidence suggests that episodes of antipsychotic discontinuation and resultant relapse episodes may be the critical factor in the evolution of emergent treatment resistance. Clozapine is recommended for TRS, however its use
requires special attention. At times combination of
non-clozapine antipsychotic drugs, electroconvulsive
treatment and newer methods, such as repetitive
transcranial magnetic stimulation (rTMS) and
transcranial direct current stimulation (tDCS) may be
considered, with lifestyle changes.
Our Faculties are:
Prof Istvan Bitter Professor of Psychiatry, Department of Psychiatry and Psychotherapy, Sommelweis University, Budapest, Hungary
Prof Robin Emsley, Professor in Psychiatry, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa
Tuesday 25th April 2022, 2 PM Central European Summer Time
02:00 pm: Welcome Prof Afzal Javed, President World Psychiatric Association
02:05 pm: Introduction of Speakers – Prof Peter Morozov, Secretary General, World Psychiatric Association
02:10 pm – 02:40 pm: Prof Istvan Bitter (Hungary) Managing treatment resistant schizophrenia
02:40 pm – 03:10 pm: Prof Robin Emsley (South Africa) Emergence of treatment resistance and illness progression associated with treatment discontinuation in schizophrenia
03:10 pm – 03:30 pm: Question and Answer
For all Enquiries please email
Free access to the webinar. For Registration, please click here: Proceed for Registration
Attendees can receive a WPA CPD Certifiate on completion of the webinar for a fee of USD $15.
This meeting is supported by an unrestricted educational grant from Viatris. The sponsor had no inflence on the design and development of the programme or any associated materials.